Clinical Trial Update: TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use [Phase 2]

View source ↗

Summary

Phase II randomized, active-controlled, open-label study evaluating etravirine (TMC125) in HIV-1 infected, protease inhibitor-naive adults with documented NNRTI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC125 (dapivirine)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infection | Phase 2 | Status: COMPLETED